The chemical examination of acetone extract of Dirinaria consimilis resulted in isolation of six depsides of which two novel metabolites namely antarvediside A (1) and antarvediside B (2) and four known metabolites i.e. sekikaic acid (3), atranorin (4), divaricatic acid (5) and 2’-O-methyl divaricatic acid (6). From the pharmacological screening of the isolates (1-6), it was found that 1 and 2 exhibited better inhibition of ABTS and superoxide free radicals than that of the standard and compound 4 showed significant inhibition of protein denaturation with IC50 value of 390 mg/mL with respect to indomethacin with 110 mg/mL. From the SRB assay results, the better IC50 values was determined by compound 2 of 10.5, 11.50 and 12.50 μg/mL on HeLa, MCF-7 and FADU cancer cell lines, respectively. Thus, the outcomes revealed that the D. consimilis is a new source to treat free radicals, inflammation and cancer.
Dirinaria consimilis的丙酮提取物的化学检验结果表明,分离出六种脱氧聚酮类化合物,其中包括两种新代谢物antarvediside A(1)和antarvediside B(2),以及四种已知代谢物,即sekikaic酸(3)、atranorin(4)、divaricatic酸(5)和2'-O-甲基divaricatic酸(6)。从所分离的化合物(1-6)的药理筛选中发现,1和2对ABTS和超氧自由基的抑制作用优于标准物质,化合物4显示出明显的蛋白变性抑制作用,IC50值为390 mg/mL,而对于110 mg/mL的吲哌酸而言,这是显著的。从SRB测定结果来看,化合物2在HeLa、MCF-7和FADU癌细胞系上的IC50值分别为10.5、11.50和12.50 μg/mL,表现出更好的抑制作用。因此,结果显示Dirinaria consimilis是一种新的来源,可用于治疗自由基、炎症和癌症。